Quantcast

Latest TRPM8 Stories

Turning Off The Cold: Neuroscientists Remove Chilly Protein From Skin
2013-02-13 07:59:08

Lawrence LeBlond for redOrbit.com - Your Universe Online Are you tired of being cold all the time? Do you wish you could turn the cold off at the push of a button? Well neuroscientists from the University of South Carolina (USC) may have some good news for you. It seems this group of researchers, led by David McKemy, associate professor of neurobiology in the USC Dornsife College of Letters, Arts and Science, have been able to isolate chilliness at the cellular level, identifying a...

2012-03-01 13:17:42

Research opening doors to treatments for stroke Researchers at St. Joseph's Hospital and Medical Center in Phoenix, Arizona, in collaboration with Amgen Inc. and several academic institutions, have discovered a way to block the body's response to cold using a drug. This finding could have significant implications in treating conditions such as stroke and cardiac arrest. The research, led by Andrej Romanovsky, MD, PhD, Director of the Systemic Inflammation Laboratory (FeverLab), which is...

2011-06-29 19:04:00

SEATTLE, June 29, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE(®) (sipuleucel-T) across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. The Los...

2011-04-06 07:00:00

SEATTLE, April 6, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following data presentations taking place at the American Association of Cancer Research (AACR) 102nd Annual Meeting 2011 in Orlando, Florida: Wednesday, April 6, 2011, 8:00 a.m. - 12:00 p.m. ET. "B lymphocytes are activated during the course of sipuleucel-T treatment, leading to an antigen-specific humoral response." Poster presentation. Wednesday, April 6, 2011, 8:00 a.m. - 12:00 p.m. ET....

2011-03-30 17:35:00

SEATTLE, March 30, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) announced today that the Centers for Medicare and Medicaid Services (CMS) has issued a proposed decision memo for PROVENGE® (sipuleucel-T). Dendreon appreciates the work and diligent scientific review conducted by CMS that resulted in the draft decision memo, in which CMS proposes that the evidence is adequate to conclude that the use of autologous cellular immunotherapy with PROVENGE improves...

2011-03-10 13:17:00

SEATTLE, March 10, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) announced today that the U.S. Food and Drug Administration (FDA) approved the remainder of its New Jersey manufacturing facility, allowing the company to significantly increase the availability of PROVENGE® (sipuleucel-T) to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Last April, upon receiving...

2010-09-14 16:00:00

SEATTLE, Sept. 14 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Ian Clark, chief executive officer and head of North American commercial operations at Genentech, a wholly-owned member of the Roche Group, has resigned from the company's Board of Directors. "It's been rewarding to serve on the board at one of the most exciting periods in Dendreon's history," said Mr. Clark. "Unfortunately, my job responsibilities currently limit the time I can devote to...

2010-09-01 06:30:00

SEATTLE, Sept. 1 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following investor conferences in September. The following presentations will be webcast: Rodman & Renshaw 12th Annual Health Care Conference, New York, NY September 13, 2010 9:35 a.m. ET Morgan Stanley 2010 Global Health Care Conference, New York, NY September 13, 2010 2:10 p.m. ET Baird's 2010 Health Care Conference, New...

2010-08-03 15:14:00

SEATTLE, Aug. 3 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended June 30, 2010. Revenue for the quarter ended June 30, 2010 was $2.8 million compared to $25,000 for the quarter ended June 30, 2009. Revenue for the six months ended June 30, 2010 was $2.8 million compared to $55,000 for the six months ended June 30, 2009. Over the first three months of launch, the company has seen revenue from sales of PROVENGE®...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.